Sign in
Phase II-I-II Study of Two Different Doses and Schedules of Pralatrexate, a High-Affinity Substrate for the Reduced Folate Carrier, in Patients With Relapsed or Refractory Lymphoma Reveals Marked Activity in T-Cell Malignancies
Journal article   Open access  Peer reviewed

Phase II-I-II Study of Two Different Doses and Schedules of Pralatrexate, a High-Affinity Substrate for the Reduced Folate Carrier, in Patients With Relapsed or Refractory Lymphoma Reveals Marked Activity in T-Cell Malignancies

Owen A O'Connor, Steven Horwitz, Paul Hamlin, Carol Portlock, Craig H Moskowitz, Debra Sarasohn, Ellen Neylon, Jill Mastrella, Rachel Hamelers, Barbara MacGregor-Cortelli, …
Journal of clinical oncology, Vol.27(26), pp.4357-4364
2009-09-10
PMCID: PMC3651599
PMID: 19652067

Abstract

url
https://doi.org/10.1200/JCO.2008.20.8470View
Published (Version of record) Open

InCites Highlights

These are selected metrics from InCites Benchmarking & Analytics tool, related to this output

Collaboration types
Domestic collaboration
Citation topics
1 Clinical & Life Sciences
1.130 Lymphomas
1.130.132 Lymphoma
Web Of Science research areas
Oncology
ESI research areas
Clinical Medicine

UN Sustainable Development Goals (SDGs)

This output has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

Source: InCites

Details